Association Between GLCCI1 Promoter Polymorphism (Rs37972) and Post-Transplant Hypertension in Renal Transplant Recipients

Abstract

Background/Aims: Post-transplant hypertension is highly prevalent in renal transplant recipients and is a risk factor for graft loss, cardiovascular disease and death. Glucocorticoid is used to prevent rejection, but simultaneously increases the risk of post-transplant hypertension. The glucocorticoid-induced transcript 1 (GLCCI1) promoter polymorphism (rs37972) has been reported to be associated with response to glucocorticoid therapy in asthma. We therefore examined the association between GLCCI1 promoter polymorphism and post-transplant hypertension in renal transplant recipients. Methods: We conducted a retrospective cohort study of renal transplantation at a single university hospital from October 2003 to January 2014. Fifty consecutive adult recipients were analyzed, with clinical data retrieved from a prospectively collected database. Genotyping was carried out using genomic DNA derived from recipient's blood. GLCCI1 immunoreactivity in vascular endothelial cells was quantitatively analyzed by immunohistochemical staining of recipients' native kidney biopsyspecimens. The primary outcome measure was post-transplant hypertension. Results: Posttransplant hypertension was observed in 14/17 (82%) of recipients with CC, 18/20 (90%) with CT, and 2/13 (15%) with TT genotype. CC/CT genotype was significantly associated with posttransplant hypertension, even after adjustment for covariates (odds ratio, 10.6; 95% confidence intervals, 1.32 to 85.8; P = 0.026). In addition, we observed that GLCCI1 immunoreactivity in

Bioinformatics Analysis of Next Generation Sequencing Data Identifies Molecular Biomarkers Associated With Type 2 Diabetes Mellitus

“…A previous study demonstrated that IGFBP5 , 223 PRDX6 , 224 PKM (pyruvate kinase M1/2) , 225 PRDX1 , 226 and USP22 227 were more highly expressed in diabetic nephropathy. Durgin et al, 228 Zhang et al, 229 Hamada et al, 230 Gong et al, 231 Li et al, 232 Lin et al, 233 and Schweigert et al 234 suggested that CYB5R3, CACNA1A, GLCCI1, CAP1, HSP90AB1, BLVRA (biliverdinreductase A), and CRIP1 were involved in the progression of hypertension. These results suggested that these, cognitive impairment, cardiovascular diseases, obesity, diabetic nephropathy and hypertension responsible genes might influence the development of T2DM through the altered expression.…”